Vivaldi Biosciences Appoints Manfred Reiter, PhD as Senior Vice President, Manufacturing

Friday, April 28, 2017

Fort Collins, CO – Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing genetically attenuated live influenza vaccines for seasonal and pandemic influenza, today announced the appointment of Manfred Reiter, PhD as Senior Vice President, Manufacturing. Dr. Reiter has responsibility for Vero cell-based production of Vivaldi’s deltaFLU live attenuated influenza vaccines (LAIVs), including process optimization, scale-up, and manufacture in compliance with global quality standards. In the near-term, Dr. Reiter will lead production of a candidate deltaFLU LAIV for the company’s planned Phase 2 clinical program to demonstrate protection in vaccinated volunteers challenged with a strain not included in the vaccine. Demonstration of such cross-protection against heterologous (unmatched) strains would be a significant advantage over currently available influenza vaccines. 

miRagen Therapeutics Presents Interim Results from MRG-201 Phase 1 Clinical Trial Demonstrating Pharmacodynamic Activity in Human Skin Incisions

Thursday, April 27, 2017

MRG-201 has been generally well-tolerated in volunteers  

ARCA biopharma Announces 200th Patient Randomized into the GENETIC-AF Seamless Design Phase 2B/3 Clinical Trial

Wednesday, April 26, 2017

WESTMINSTER, Colo.--(BUSINESS WIRE)--ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that the 200th patient has been randomized into the GENETIC-AF clinical trial evaluating Gencaro™ (bucindolol hydrochloride) as potentially the first genetically-targeted treatment for atrial fibrillation (AF). 

Silvergate Pharmaceuticals: FDA Approves XATMEP™, the First and Only Ready-To-Use Methotrexate Oral Solution

Wednesday, April 26, 2017

Denver, April 26, 2017 — Silvergate Pharmaceuticals, Inc. ( leaders in the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration (FDA) approved XATMEP (methotrexate) Oral Solution, the first and only FDA-approved methotrexate oral solution. XATMEP is indicated for the treatment of acute lymphoblastic leukemia (ALL) and polyarticular juvenile idiopathic arthritis (pJIA) in pediatric patients. 

CSSi LifeSciences Executives Featured at Colorado BioScience Association BioBoot Camp 2017

Monday, April 24, 2017

Glen Burnie, MD (April 21, 2017) – Today, Friday, April 21, 2017, members of CSSi LifeSciences™’s executive team served as featured speakers for BioBoot Camp 2017, a signature program produced by the Colorado BioScience Association (CBSA). Jim Sergi, President of CSSi LifeSciences, and Heidi Nelson-Keherly, Ph.D., Executive Director of Preclinical Research at CSSi LifeSciences, provided real-world insights on successfully transitioning innovations into the marketplace to 30 life science start-ups from all across the state of Colorado. 

miRagen Therapeutics to Present MRG-201 Data at the Society for Investigative Dermatology Annual Meeting

Thursday, April 20, 2017

BOULDER, CO –April 20, 2017 – Miragen Therapeutics, Inc. (Nasdaq: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, announced today that interim results from its ongoing Phase 1 clinical study of MRG-201 will be presented at the Society for Investigative Dermatology (SID) 76th Annual Meeting being held April 26-29, 2017 in Portland, Oregon. 

Innosphere Launches Investor Network

Wednesday, April 19, 2017

Colorado - Innosphere, Colorado's leading incubator for science and technology startups, has formally launched an investor network to support investment into Innosphere client companies. The Innosphere Investor Network is a group of active, accredited investors seeking highly-vetted, investment-ready opportunities. 

Cerapedics receives $20 million loan from Oxford Finance

Wednesday, April 19, 2017

Cerapedics, Inc., a Westminster, CO-based orthobiologics company engaged in the development and commercialization of bone graft substitute products for the treatment of orthopedic injuries, received a $20m senior secured term loan. 

PharmaJet wins 2017 Colorado Manufacturing Awards for innovation in its category

Tuesday, April 18, 2017


Cliexa's rheumatoid arthritis app scores as the 2nd best RA app out of more than 900 tested

Tuesday, April 18, 2017

Cliexa-RA, Cliexa's rheumatoid arthritis app, has been scored as the 2nd best RA app among 19 best apps selected from 900+ apps to NIH research.